文献速递前列腺增生与排尿功能障碍

米拉贝隆与奥纳布妥昔单抗A在既往接受抗胆碱能药物治疗的膀胱过度活动症患者中的相对疗效与安全性:一项网络Meta分析

The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis.
PubMed 文献 · Urology · 2019-02-18

本研究通过系统文献综述随机对照试验及米拉贝隆治疗经验亚组的事后分析,纳入21篇出版物描述的19项试验,进行网络Meta分析,比较米拉贝隆与奥纳布妥昔单抗A在治疗经验患者中的疗效与安全性。结果显示,奥纳布妥昔单抗A在减少24小时排尿次数和尿失禁发作次数方面有一定证据优于米拉贝隆,但米拉贝隆的尿路感染风险较低。

要点

  • 奥纳布妥昔单抗A在减少24小时排尿次数和尿失禁发作次数方面有一定证据优于米拉贝隆。
  • 米拉贝隆相比奥纳布妥昔单抗A与更低的尿路感染风险相关。
  • 证据来自19项随机对照试验及米拉贝隆治疗经验亚组的事后分析。

核心结论

  • 总体而言,与米拉贝隆相比,有一定证据表明奥纳布妥昔单抗A与结局改善相关,包括减少24小时排尿次数和尿失禁发作次数。
  • 然而,与奥纳布妥昔单抗A相比,米拉贝隆与更低的尿路感染风险相关。

研究设计与样本

  • 网络Meta分析基于随机对照试验的系统文献综述以及米拉贝隆研究中治疗经验亚组的事后分析。
  • 共纳入21篇出版物描述的19项试验。

主要发现

  • 与米拉贝隆相比,有一定证据表明奥纳布妥昔单抗A与24小时排尿次数减少相关。
  • 与米拉贝隆相比,有一定证据表明奥纳布妥昔单抗A与尿失禁发作次数减少相关。
  • 与奥纳布妥昔单抗A相比,米拉贝隆与更低的尿路感染风险相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To compare the efficacy and safety of mirabegron and onabotulinumtoxinA in the management of treatment-experienced patients with overactive bladder. METHODS: The network meta-analysis was based on evidence from a systematic literature review of randomized controlled trials and a post-hoc analysis of treatment-experienced subpopulations from mirabegron studies. RESULTS: Nineteen trials described in 21 publications were included. CONCLUSION: Overall, compared to mirabegron, there was some evidence that onabotulinumtoxinA was associated with improved outcomes, including reductions in the number of micturitions in a 24-hour period, and the number of incontinence episodes. However, mirabegron was associated with a lower risk of urinary tract infections compared with onabotulinumtoxinA.

来源:Urology,查看原文。版权归原作者所有。

引用

  1. Lozano-Ortega G, Walker D, Rogula B, et al. The Relative Efficacy and Safety of Mirabegron and OnabotulinumtoxinA in Patients With Overactive Bladder who Have Previously Been Managed With an Antimuscarinic: A Network Meta-analysis. Urology. 2019. PMID: 30790650. doi:10.1016/j.urology.2019.02.005

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。